Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

HOEFMAN LABORATOIRES : revenue, balance sheet and financial ratios

HOEFMAN LABORATOIRES is a French company founded 5 years ago, specialized in the sector Fabrication de produits pharmaceutiques de base. Based in NICE (06000), this company of category PME shows in 2025 a net income negative of -385 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - HOEFMAN LABORATOIRES (SIREN 891307902)
Indicator 2025 2024 2023 2022 2021
Revenue N/C N/C N/C N/C N/C
Net income -384 844 € 408 348 € 111 988 € 292 744 € 66 632 €
EBITDA N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C

Revenue and income statement

Im Jahr 2025 verzeichnet HOEFMAN LABORATOIRES einen Nettoverlust von 385 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-384 844 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

Die Verschuldungsquote (= Finanzschulden / Eigenkapital x 100) beträgt 299%. Kritische Situation: Die Schulden übersteigen das Eigenkapital erheblich. Die finanzielle Autonomie (= Eigenkapital / Bilanzsumme x 100) erreicht 15%. Geringe Autonomie: Das Unternehmen ist stark von externer Finanzierung abhängig.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

298.639%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

15.077%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

54.0%

Solvency indicators evolution
HOEFMAN LABORATOIRES

Sector positioning

Verschuldungsgrad
20.98 2024
2023
2024
Q1: 0.0
Med: 3.24
Q3: 65.34
Average

Im Jahr 2024 liegt über dem Median der Branche das verschuldungsgrad von HOEFMAN LABORATOIRES (20.98). Dieses Verhältnis misst das Gewicht der Schulden im Verhältnis zum Eigenkapital. Eine Reduzierung könnte die finanzielle Stärke verbessern.

Finanzielle Autonomie
43.56% 2024
2023
2024
Q1: 17.24%
Med: 45.12%
Q3: 75.14%
Average

Im Jahr 2024 liegt unter dem Median der Branche das finanzielle autonomie von HOEFMAN LABORATOIRES (43.6%). Dieses Verhältnis stellt den Anteil des Eigenkapitals an der Gesamtfinanzierung dar. Eine Verbesserung würde die Wettbewerbsposition stärken.

Liquidity ratios

Die Liquiditätsquote beträgt 203.40. Das Unternehmen verfügt über 2€ liquide Mittel für jeden 1€ kurzfristiger Schulden.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

203.395

Liquidity indicators evolution
HOEFMAN LABORATOIRES

Sector positioning

Liquiditätsquote
195.13 2024
2023
2024
Q1: 92.26
Med: 208.82
Q3: 371.21
Average +11 pts over 2 years

Im Jahr 2024 liegt unter dem Median der Branche das liquiditätsquote von HOEFMAN LABORATOIRES (195.13). Dieses Verhältnis misst die Fähigkeit, kurzfristige Schulden mit Umlaufvermögen zu decken. Eine Verbesserung würde die Wettbewerbsposition stärken.

Working capital requirement (WCR) and payment terms

Der Betriebskapitalbedarf (WCR) misst die zeitliche Lücke.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
HOEFMAN LABORATOIRES

Positioning of HOEFMAN LABORATOIRES in its sector

Comparison with sector Fabrication de produits pharmaceutiques de base

Similar companies (Fabrication de produits pharmaceutiques de base)

Compare HOEFMAN LABORATOIRES with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de produits pharmaceutiques de base

Frequently asked questions about HOEFMAN LABORATOIRES

What is the revenue of HOEFMAN LABORATOIRES ?

The revenue of HOEFMAN LABORATOIRES is not publicly disclosed (confidential accounts filed with INPI).

Is HOEFMAN LABORATOIRES profitable?

HOEFMAN LABORATOIRES recorded a net loss in 2025.

Where is the headquarters of HOEFMAN LABORATOIRES ?

The headquarters of HOEFMAN LABORATOIRES is located in NICE (06000), in the department Alpes-Maritimes.

Where to find the tax return of HOEFMAN LABORATOIRES ?

The tax return of HOEFMAN LABORATOIRES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does HOEFMAN LABORATOIRES operate?

HOEFMAN LABORATOIRES operates in the sector Fabrication de produits pharmaceutiques de base (NAF code 21.10Z). See the 'Sector positioning' section above to compare the company with its competitors.